Abstract: To develop an accurate and sensitive ultra-performance liquid chromatography-tandem mass spectrometry(UPLC-MS) method for determination of apigenin-7-O-glucronide in rat plasma and study the pharmacokinetics of apigenin-7-O-glucronide in normal rat and middle cerebral artery occlusion(MCAO) rat.MCAO model was established by meliorative Zea longa method.Normal group and model group were given orally with Erigeron breviscapus extract.The concentrations of apigenin-7-O-glucronide in rat plasma of normal group and model group were compared after oral administration of the same dose of E.breviscapus extract.Compared with normal group,the values of AUC and C_max increased and the values of  Cl_Z/F, V_Z/F and MRT decreased in model group.The results indicated that bioavailability of model group increased remarkably,which reflected the rationality of apigenin-7-O-glucronide in the clinical treatment of cerebral ischemia diseases.

Key words: UPLC-MS, Erigeron breviscapus;apigenin-7-O-glucronide;middle cerebral artery occlusion model;pharmacokinetics